Raesedo

RaeSedo, Inc. is a biotechnology company pioneering SP-A-based structural peptidomimetics for the treatment of asthma and other lung diseases. The company develops inhaled therapies designed to reduce lung inflammation and mucus by leveraging surfactant protein-A (SP-A) research. In 2024, RaeSedo was selected to present its novel asthma approach at a major pharma industry forum.